In the United States a plethora of pharmacological treatments from an array of drug classes are available to patients with major depressive disorder (MDD), a highly drug-treated condition. Though the MDD drug market is highly entrenched with generic therapies, MDD patients’ heterogeneous responses to antidepressants and/or atypical antipsychotics afford branded drugs (e.g., Trintellix [Lundbeck / Takeda], Rexulti [Otsuka / Lundbeck]) the opportunity to be introduced into the treatment paradigm, often as later-line therapies. Given MDD’s highly crowded and competitive landscape, it is valuable for drug marketers and developers to understand how MDD patients are being treated using real-world data.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients?
  • How has Lundbeck / Otsuka’s Rexulti (brexpiprazole) been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of MDD patients receive Lundbeck / Takeda’s Trintellix (vortioxetine) within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of MDD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Real world data: Longitudinal patient-level claims data analysis

Key companies: Allergan, Eli Lilly, Lundbeck, Otsuka, Sunovion, Takeda

Key drugs: Aripiprazole (Abilify, aripiprazole), citalopram (Celexa, generics), duloxetine (Cymbalta, generics), Fetzima, Latuda, Rexulti, Trintellix, Viibryd

Key analysis provided:

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow charts

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis
    • Treatment Algorithms CDA - Major Depressive Disorder - US - May 2019

Author(s): Bethany A. Kiernan, PhD

Bethany A. Kiernan, is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders. Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her degree from Case Western Reserve University.


Related Reports

Unipolar Depression | Access & Reimbursement | Detailed, Expanded Analysis (US) Major Depressive Disorder

Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD

View Details